The Phase II clinical trials of Soberana Plus in convalescents of COVID 19 will include 450 people and will broaden the inclusion criteria compared to Phase I, informed today an expert from the Finlay Vaccine Institute (IFV), the entity that developed this vaccine candidate against COVID-19.

Solidarity organizations and Cuban residents in European countries carry out a campaign to send a container to Cuba with supplies intended to support immunization against Covid-19, said Reynaldo Romero, project coordinator today.

Cuba is prepared for the most worrying mutation of SARS-CoV-2 so far, the E484K, which decreases to a greater extent the neutralizing capacity of antibodies, both in convalescents and vaccinated people.

Five genetic variants and six mutational patterns of SARS-CoV-2, the pathogen that causes Covid-19, are currently circulating in Cuba, health authorities informed.